Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mayo Clinic

Sites in Jacksonville, FL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 2:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
706
Shown on this page
12
Current sort
Recently updated
Campus scope
Mayo Clinic, Jacksonville, FL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Mayo Clinic, Jacksonville, FL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 685–696 of 706 matching trials with a site at Mayo Clinic, Jacksonville, FL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting No phase listed Observational Accepts healthy volunteers

Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium

NCT06284213
Site status not listed — check the official record
View directory record Official record
Conditions
Cognitive Impairment, Dementia
Interventions
No interventions
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 90 Years
Enrollment
1,892 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 27, 2026, 2:45 PM EDT
Active, not recruiting Phase 3 Interventional

Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

NCT03992755
Site status not listed — check the official record
View directory record Official record
Conditions
Primary Pulmonary Hypertension
Interventions
LIQ861 Inhaled Treprostinil
Drug
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 27, 2026, 2:45 PM EDT
Active, not recruiting Phase 1 Interventional

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

NCT04623944
Site status not listed — check the official record
View directory record Official record
Conditions
Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes
Interventions
NKX101 - CAR NK cell therapy
Biological
Lead sponsor
Nkarta, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2039
U.S. locations
8
States / cities
Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 27, 2026, 2:45 PM EDT
Recruiting No phase listed Observational

Safety and Durability of Sirolimus for Treatment of LAM

NCT02432560
Status at this site: Recruiting
View directory record Official record
Conditions
Lymphangioleiomyomatosis
Interventions
Sirolimus, Everolimus
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
20
States / cities
Stanford, California • Denver, Colorado • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 27, 2026, 2:45 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT03553836
Site status not listed — check the official record
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
12 Years and older
Enrollment
976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2033
U.S. locations
39
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 27, 2026, 2:45 PM EDT
Recruiting Not applicable Interventional

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

NCT03860883
Status at this site: Recruiting
View directory record Official record
Conditions
Cutaneous Melanoma, Stage II
Interventions
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Procedure
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Other
Eligibility
18 Years and older
Enrollment
2,998 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
128
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 27, 2026, 2:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

NCT05824975
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Interventions
GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab
Drug
Lead sponsor
GI Innovation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 27, 2026, 2:45 PM EDT
Recruiting Phase 2 Interventional

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

NCT06160206
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma
Interventions
Bevacizumab, Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Retifanlimab
Biological · Procedure · Other + 1 more
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 27, 2026, 2:45 PM EDT
Recruiting No phase listed Observational

Customized TULSA-PRO Ablation Registry

NCT05001477
Status at this site: Recruiting
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Benign Prostatic Hyperplasia
Interventions
TULSA Procedure
Device
Lead sponsor
Profound Medical Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2061
U.S. locations
5
States / cities
West Hills, California • Jacksonville, Florida • York, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 27, 2026, 2:45 PM EDT
Active, not recruiting Phase 3 Interventional

Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH

NCT05995405
Site status not listed — check the official record
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage (aSAH)
Interventions
GTX-104, Nimotop 30 MG Oral Capsule
Drug
Lead sponsor
Grace Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 27, 2026, 2:45 PM EDT
Recruiting Phase 1 Interventional

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

NCT06259552
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumor, HNSCC, RCC, CRC
Interventions
SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody
Biological
Lead sponsor
SparX Biotech(Jiangsu) Co., Ltd.
Other
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 27, 2026, 2:45 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

NCT03796962
Site status not listed — check the official record
View directory record Official record
Conditions
Focal Epilepsy
Interventions
XEN1101
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
54
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 27, 2026, 2:45 PM EDT

About this Mayo Clinic institution page

What this page lists
ClinicalTrials.gov records that list Mayo Clinic in Jacksonville, FL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Mayo Clinic at any site, browse by condition, or browse by U.S. city.